LAPaL
THE LONG-ACTING THERAPEUTICS PATENTS AND LICENCES DATABASE

Developed by

medicines patent pool

UNIVERSITY OF LIVERPOOL

CELT

Supported by

Unitaid
SAVE LIVES FASTER

leap



Tenofovir-Lamivudine-Dolutegravir (TLD) - long-acting injectable (LAI) (TLD LAI)

Developer(s)

University of Washington

https://www.washington.edu/

United States

The University of Washington is a public research university based in Seattle, Washington, USA. Originally founded in 1861, the institution has an extraordinary track record of scientific inventions & discoveries. Its Targeted Long-acting Combination Antiretroviral Therapy (TLC-ART) program aims to develop safe, stable, scalable and tolerable long-acting ART combinations for the treatment of HIV.

Drug structure



tenofovir (aka GS 1278 aka PMPA)

MedChemExpress



lamivudine (aka BCH-189)

MedChemExpress



dolutegravir (aka S/GSK1349572)

Drug information

Associated long-acting platforms

Aqueous drug particle suspension, Based on other organic particles

Administration route

Subcutaneous

Therapeutic area(s)

HIV
HBV

Use case(s)

Treatment

Use of drug

Ease of administration

Administered by a nurse
Administered by a specialty health worker
Self-administered
Administered by a community health worker
To be determined

User acceptance

Not provided

Dosage

Available dose and strength

Not provided

Frequency of administration

Not provided

Maximum dose

Not provided

Recommended dosing regimen

Not provided

Additional comments

Not provided

Dosage link(s)

Not provided

Drug information

Drug's link(s)

Not provided

Generic name

Not yet developed

Brand name

Not yet assigned

Compound type

Small molecule

Summary

Tenofovir disoproxil fumarate/Lamivudine/Dolutegravir (TLD; TDF/3TC/DTG) is a fixed-dose antiretroviral drug combination used for the treatment of HIV. It consists of two NNRTIs (TDF/3TC) and an InSTI (DTG). Since 2018, WHO HIV treatment guidelines have recommended daily oral TLD as the preferred first-line regimen for initiating antiretroviral therapy (ART) among adults and adolescents living with HIV. In most PEPFAR-supported countries, more than 80% of people receiving HIV-ART were prescribed oral TLD as of March 2022. Researchers at the University of Washington are currently developing a long-acting injectable version of tenofovir+lamivudine+dolutegravir via drug-combination-nanoparticle (DcNP) technology platform which would enable effective TLD concentrations for up to 4 weeks.

Approval status

Still in clinical development

Regulatory authorities

Still in clinical development

Delivery device(s)

No delivery device

Scale-up and manufacturing prospects

Scale-up prospects

A novel long-acting TLD drug-combination nano-particulate (DcNP) formulation for subcutaneous injection was prepared with biocompatible lipid excipients. The highly-scalable DcNP technology enables drugs with disparate physiochemical properties to be formulated into products that remain stable in aqueous suspension. First, TLD was dissolved with lipid-excipients in hydrated-alcohol, followed by a controlled solvent-removal process to create the TLD-DcNP powder. Next, the TLD-DcNP particle-size was reduced (60-80 nm) resulting in a stable-injectable TLD product suitable for subcutaneous dosing.

Tentative equipment list for manufacturing

Rotary evaporator (rotavap). High pressure homogeniser (e.g. Emulsiflex-c5; Avestin Inc., Canada). Spray-dryer (e.g. 4M8Trix Unit; ProCepT, Belgium).

Manufacturing

TLD-in-DcNP injectable suspension was prepared by dissolving 40.27 mmol DSPC, 5.97mmol HCl, 5.66 mmol DTG and 4.49mmol mPEG2000-DSPE in 472 ml ethanol at 70°C. Following dissolution, 28 ml of 200 mM $NaHCO_3$ buffer containing 5.85 mmol TFV and 5.85 mmol 3TC was added. The solution was then spray-dried under controlled-solvent-removal process to generate the TLD-in-DcNP powder. The powder in 0.45% w/v NaCl–20 mM $NaHCO_3$ buffer suspension was held at 75°C and homogenised to achieve stable particles (50–70 nm). The suspension was cooled to 25°C and stored at 4°C.

Specific analytical instrument required for characterization of formulation

Particle size determined by photon correlation spectroscopy using a NICOMP 380 ZLS (Particle Sizing Systems, Santa Barbara, CA). Osmolality (Vapro 5520 osmometer; Wescor, Logan, UT) and pH (Hydrion paper). Drug quantification via LC-MS/MS using acetonitrile precipitation.

Clinical trials

Not provided

Excipients

Proprietary excipients used

Lipid excipients: DSPC and DSPE-mPEG2000

Novel excipients or existing excipients at a concentration above Inactive Ingredients Database (IID) for the specified route of administration

Not provided

Residual solvents used

Not provided

Patent info

Compound patent families

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
TAF manufacturing process Expiry date: 2032-10-03 Methods for isolating 9-{(R)-2-[((S)-{[(S)-l -(isopropoxycarbonyl)ethyl]amino}phenoxyphosphinyl)methoxy]propyl}adenine:'' (compound 16): a method for preparing, in high diastereomeric purity, intermediate compounds 13 and 15: method for preparing intermediate compound 12: 9-{(R)-2-[((S)-{[(S)-l -(isopropoxycarbonyl)ethyl]amino}phenoxyphosphinyl)methoxy]propyl}adenine has anti-viral properties.	WO2013052094	Process	Gilead Sciences, Inc	Yes	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income

Granted	China, Colombia, Mexico, Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Tajikistan, Turkmenistan, Türkiye, Bosnia and Herzegovina, Montenegro	Australia, Canada, Hong Kong, Japan, Korea, Republic of, Taiwan, Province of China, United States of America, Russian Federation, Austria, Belgium, Switzerland, Czechia, Germany, Spain, France, United Kingdom, Greece, Hungary, Ireland, Italy, Liechtenstein, Netherlands, Norway, Poland, Portugal, Sweden, Slovenia, Slovakia, New Zealand, Israel
Filed	China	Hong Kong, Korea, Republic of
Not in force	Argentina, Costa Rica, Peru, Albania, North Macedonia, Serbia, Türkiye, World Intellectual Property Organization (WIPO), Brazil, Bosnia and Herzegovina, Montenegro, Ecuador	Chile, Japan, Uruguay, Bulgaria, Cyprus, Czechia, Denmark, Estonia, Finland, Greece, Croatia, Hungary, Iceland, Lithuania, Luxembourg, Latvia, Monaco, Malta, Norway, Poland, Romania, Slovenia, Slovakia, San Marino, World Intellectual Property Organization (WIPO)

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on tenofovir disoproxil fumarate (TDF)

https://medicinespatentpool.org/licence-post/tenofovir-disoproxil-fumarate-tdf/

MPP licence on paediatric formulations of dolutegravir (DTG)

https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/

Compulsory licence on dolutegravir in Colombia

https://www.statnews.com/wp-

content/uploads/2024/04/NC_534_Licencia_obligatoria_aceptada.pdf

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Tenofovir alafenamide hemifumarate (TAF) Expiry date: 2032-08-15 A hemifumarate form of tenofovir alafenamide, and antiviral therapy using tenofovir alafenamide hemifurnarate (e.g., anti-HTV and anti-HBV therapies).	WO2013025788	Salt	Gilead Sciences, Inc	Yes	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted	Costa Rica, Morocco, Moldova, Republic of, Mexico, Peru, Botswana, Ghana, Gambia (the), Kenya, Liberia, Lesotho, Malawi, Mozambique, Namibia, Rwanda, Sudan, Sierra Leone, Eswatini, Tanzania, United Republic of, Uganda, Zambia, Zimbabwe, Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Tajikistan, Turkmenistan, Viet Nam, Benin, Cameroon, Burkina Faso, Chad, Guinea-Bissau, Mali, Senegal, Congo, Guinea, Gabon, Niger, Equatorial Guinea, Mauritania, Togo, Côte d'Ivoire, Central African Republic, Bolivia (Plurinational State of), Philippines, South Africa, Ukraine, Brazil, El Salvador, Montenegro, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Serbia	United States of America, Australia, Canada, Chile, Hong Kong, Israel, Japan, Korea, Republic of, New Zealand, Singapore, Taiwan, Province of China, Uruguay, Russian Federation, Denmark, Slovenia, Panama, Croatia, San Marino, Cyprus, Bahamas, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Monaco, Portugal, Ireland, Finland, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, Romania, Latvia, Lithuania

Patent status/countries	Low, Low- middle and upper-middle	High income
Filed	China, Ecuador, India, Paraguay, Thailand, Venezuela (Bolivarian Republic of), Türkiye, North Macedonia, Albania, Serbia, Egypt	Hong Kong, Denmark, Slovenia, Bahrain, Kuwait, Qatar, Saudi Arabia, Oman, United Arab Emirates, Croatia, San Marino, Cyprus, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Monaco, Portugal, Ireland, Finland, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, Romania, Latvia, Lithuania
Not in force	World Intellectual Property Organization (WIPO), Argentina, China, Colombia, Indonesia, Pakistan, Brazil, Montenegro, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Serbia	World Intellectual Property Organization (WIPO), Hong Kong, Israel, Japan, New Zealand, Denmark, Slovenia, Croatia, San Marino, Cyprus, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Monaco, Portugal, Ireland, Finland, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, Romania, Latvia, Lithuania

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on tenofovir disoproxil fumarate (TDF)

https://medicinespatentpool.org/licence-post/tenofovir-disoproxil-fumarate-tdf/

MPP licence on paediatric formulations of dolutegravir (DTG)

https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/

Compulsory licence on dolutegravir in Colombia

https://www.statnews.com/wp-content/uploads/2024/04/NC_534_Licencia_obligatoria_aceptada.pdf

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Dolutegravir in combination with lamivudine (3TC) Expiry date: 2031-01-24 The present disclosure relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations may be useful in the inhibition of HIV-1 or potentially the inhibition of HIV replication, or for the prevention and/or treatment of infection by HIV, or in the treatment of AIDS and/or ARC.	CA3003988	Combination	Viiv Healthcare Company	Yes	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted	Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia, Mexico	United States of America, Canada, Australia, Russian Federation, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia, Israel
Filed	Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia	Singapore, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia

Patent status/countries	Low, Low- middle and upper-middle	High income
Not in force	Moldova, Republic of, Dominican Republic	United States of America, Australia

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on tenofovir disoproxil fumarate (TDF)

https://medicinespatentpool.org/licence-post/tenofovir-disoproxil-fumarate-tdf/

MPP licence on paediatric formulations of dolutegravir (DTG)

https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/

Compulsory licence on dolutegravir in Colombia

https://www.statnews.com/wp-content/uploads/2024/04/NC_534_Licencia_obligatoria_aceptada.pdf

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Dolutegravir or cabotegravir in combination with ABC, 3TC or RPV Expiry date: 2031-01-24 The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.	WO2011094150	Combination	Glaxosmithkline Llc, Underwood, Mark Richard	Yes	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted	Malaysia, Philippines	Hong Kong
Filed	Algeria, Egypt, Thailand, Malaysia, Philippines, Viet Nam	Oman
Not in force	Costa Rica, Ecuador, Libya, World Intellectual Property Organization (WIPO), Brazil, Tajikistan, Belarus, Azerbaijan, Moldova, Republic of, Turkmenistan, Armenia, Kyrgyzstan, Kazakhstan	Hong Kong, World Intellectual Property Organization (WIPO), Russian Federation

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on tenofovir disoproxil fumarate (TDF)

https://medicinespatentpool.org/licence-post/tenofovir-disoproxil-fumarate-tdf/

MPP licence on paediatric formulations of dolutegravir (DTG)

https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/

Compulsory licence on dolutegravir in Colombia

https://www.statnews.com/wp-content/uploads/2024/04/NC_534_Licencia_obligatoria_aceptada.pdf

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Dolutegravir/Cabotegravir intermediates production processes & Intermediates Expiry date: 2029-12-09 Processes are provided which create an aldehyde methylene, or hydrated or hemiacetal methylene attached to a heteroatom of a 6 membered ring without going through an olefinic group and without the necessity of using an osmium reagent. In particular, a compound of formula (I) can be produced from (II) and avoid the use of an allyl amine: (formulae I and II) where R, P 1 P3, R3 and Rx are as described herein.	WO2010068262	Intermediates, Process	Shionogi & Co., Ltd, Viiv Healthcare Company	Yes	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted	China, India, North Macedonia	Japan, Korea, Republic of, Singapore, Taiwan, Province of China, United States of America, Portugal, Belgium, Germany, France, Netherlands, Switzerland, United Kingdom, Italy, Liechtenstein, Spain, Finland, Cyprus, Hungary
Filed		Portugal, Spain
Not in force	China, World Intellectual Property Organization (WIPO), Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Serbia	World Intellectual Property Organization (WIPO), Luxembourg, Sweden, Austria, Greece, Denmark, Monaco, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on tenofovir disoproxil fumarate (TDF)

https://medicinespatentpool.org/licence-post/tenofovir-disoproxil-fumarate-tdf/

MPP licence on paediatric formulations of dolutegravir (DTG)

https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/

Compulsory licence on dolutegravir in Colombia

https://www.statnews.com/wp-content/uploads/2024/04/NC_534_Licencia_obligatoria_aceptada.pdf

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Dolutegravir salts, their crystals & process Expiry date: 2029-12-08 A synthesis approach providing an early ring attachment via a bromination to compound I-I yielding compound II-II, whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.	WO2010068253	Process, Salt	Glaxosmithkline Llc, Johns, Brian, Alvin, Shionogi & Co., Ltd, Taoda, Yoshiyuki, Yoshida, Hiroshi	Yes	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted	China, Mexico, Brazil, Indonesia, India	United States of America, Australia, Canada, Switzerland, Germany, Spain, France, United Kingdom, Ireland, Italy, Liechtenstein, Japan, Korea, Republic of, Russian Federation, Singapore, Taiwan, Province of China
Filed		Canada
Not in force	World Intellectual Property Organization (WIPO), North Macedonia, Türkiye, India	World Intellectual Property Organization (WIPO), Austria, Belgium, Bulgaria, Switzerland, Cyprus, Czechia, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Croatia, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Luxembourg, Latvia, Monaco, Malta, Netherlands, Norway, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, San Marino, Hong Kong

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on tenofovir disoproxil fumarate (TDF)

https://medicinespatentpool.org/licence-post/tenofovir-disoproxil-fumarate-tdf/

MPP licence on paediatric formulations of dolutegravir (DTG)

https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/

Compulsory licence on dolutegravir in Colombia

https://www.statnews.com/wp-content/uploads/2024/04/NC_534_Licencia_obligatoria_aceptada.pdf

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Cabotegravir prodrugs & Cabotegravir and Dolutegravir intermediates and processes Expiry date: 2029-07-23 The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the delivery of compounds for the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.	WO2010011814	Intermediate(s), Process	Glaxosmithkline Llc, Shionogi & Co., Ltd, Viiv Healthcare Company	Yes	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted	China, India	Belgium, Germany, France, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Liechtenstein, Spain, Portugal, Japan, Korea, Republic of, Singapore, United States of America
Filed		Spain, Portugal
Not in force	Türkiye, North Macedonia, Bosnia and Herzegovina, World Intellectual Property Organization (WIPO), Albania, Serbia	Belgium, France, Luxembourg, Netherlands, Switzerland, Sweden, Austria, Liechtenstein, Greece, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia, World Intellectual Property Organization (WIPO)

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on tenofovir disoproxil fumarate (TDF)

https://medicinespatentpool.org/licence-post/tenofovir-disoproxil-fumarate-tdf/

MPP licence on paediatric formulations of dolutegravir (DTG)

https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/

Compulsory licence on dolutegravir in Colombia

https://www.statnews.com/wp-content/uploads/2024/04/NC_534_Licencia_obligatoria_aceptada.pdf

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Dolutegravir and Cabotegravir compounds Expiry date: 2026-04-28 The present invention is to provide a novel compound (I), having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. Compound (I) wherein Z<1> is NR<4>; R<1> is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R<2> is optionally substituted aryl; R<3> is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R<4> and Z<2> part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.	WO2006116764	Compound	Glaxosmithkline Llc	Yes	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income

Granted	Brazil, China, Morocco, Mexico, Philippines, Ukraine, Viet Nam, South Africa, Türkiye, Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Republic of, Tajikistan, Turkmenistan, Nigeria, Colombia, Indonesia, Malaysia, Algeria	United States of America, Australia, Canada, Cyprus, Hong Kong, Israel, Japan, Korea, Republic of, Luxembourg, Norway, New Zealand, Taiwan, Province of China, Austria, Belgium, Bulgaria, Switzerland, Czechia, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Latvia, Monaco, Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, Russian Federation, Trinidad and Tobago, Singapore
Filed	Egypt	United States of America, Cyprus, Luxembourg, Norway, Finland, France, Hungary, Lithuania, Netherlands, Slovenia
Not in force	Türkiye, India, World Intellectual Property Organization (WIPO)	United States of America, Cyprus, Hong Kong, Israel, Japan, Luxembourg, Austria, Belgium, Bulgaria, Switzerland, Czechia, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Latvia, Monaco, Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, World Intellectual Property Organization (WIPO)

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on tenofovir disoproxil fumarate (TDF)

https://medicinespatentpool.org/licence-post/tenofovir-disoproxil-fumarate-tdf/

MPP licence on paediatric formulations of dolutegravir (DTG)

https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/

Compulsory licence on dolutegravir in Colombia

https://www.statnews.com/wp-content/uploads/2024/04/NC_534_Licencia_obligatoria_aceptada.pdf

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Tenofovir alafenamide fumarate (TAF) Expiry date: 2021-07-20 A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein.	WO0208241	Compound	Gilead Sciences, Inc	Yes	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income

Granted	Ukraine, Albania, Ethiopia, Fiji, Grenada, Kiribati, Solomon Islands, Saint Lucia	Australia, Bulgaria, Denmark, Estonia, Hong Kong, Croatia, Hungary, Israel, Iceland, Japan, Korea, Republic of, Poland, Slovenia, United States of America, Russian Federation, Belgium, Switzerland, Cyprus, Germany, Finland, France, United Kingdom, Greece, Italy, Liechtenstein, Luxembourg, Netherlands, Sweden, Lithuania, Romania, Latvia, Brunei Darussalam, Czechia, Anguilla, Bermuda, Falkland Islands (Malvinas), Montserrat, Turks and Caicos Islands, Virgin Islands (British), Saint Helena, Ascension and Tristan da Cunha, Singapore, Cayman Islands, Gibraltar, Guernsey
Filed	Jamaica	Australia, Denmark, Spain, Norway, Portugal, Slovenia, Cyprus, Finland, France, Lithuania
Not in force	China, Mexico, Türkiye, South Africa, Ghana, Gambia (the), Kenya, Lesotho, Malawi, Mozambique, Sudan, Sierra Leone, Eswatini, Tanzania, United Republic of, Uganda, Zimbabwe, Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Republic of, Tajikistan, Turkmenistan, Burkina Faso, Benin, Central African Republic, Congo, Côte d'Ivoire, Cameroon, Gabon, Guinea, Equatorial Guinea, Guinea-Bissau, Mali, Mauritania, Niger, Senegal, Chad, Togo, India, Indonesia, Viet Nam, World Intellectual Property Organization (WIPO), North Macedonia, Albania, Congo, democratic Republic of the, Haiti, Nepal, Tuvalu, Brazil	Canada, Australia, Denmark, Spain, Hong Kong, Croatia, Japan, Norway, New Zealand, Portugal, Slovenia, United States of America, Austria, Belgium, Switzerland, Cyprus, Germany, Finland, France, United Kingdom, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, Netherlands, Sweden, World Intellectual Property Organization (WIPO), Lithuania, Romania, Latvia, Czechia, Guyana, Seychelles, Jersey

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on tenofovir disoproxil fumarate (TDF)

https://medicinespatentpool.org/licence-post/tenofovir-disoproxil-fumarate-tdf/

MPP licence on paediatric formulations of dolutegravir (DTG)

https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/

Compulsory licence on dolutegravir in Colombia

https://www.statnews.com/wp-content/uploads/2024/04/NC_534_Licencia_obligatoria_aceptada.pdf

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Tenofovir disoproxil fumarate (TDF) Expiry date: 2018-07-23 The invention provides a composition comprising bis(POC)PMPA and fumaric acid (1:1). The composition is useful as an intermediate for the preparation of antiviral compounds, or is useful for administration to patients for antiviral therapy or prophylaxis. The composition is particularly useful when administered orally. The invention also provides methods to make PMPA and intermediates in PMPA synthesis. Embodiments include lithium t-butoxide, 9-(2-hydroxypropyl) adenine and diethyl p-toluenesulfonylmethoxy-phosphonate in an organic solvent such as DMF. The reaction results in diethyl PMPA preparations containing an improved by-product profile compared to diethyl PMPA made by prior methods	WO9905150	Compound, Salt	Gilead Sciences, Inc	Yes	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted		
Filed		Portugal

Patent status/countries	Low, Low- middle and upper-middle	High income
Not in force	Brazil, China, India, Mexico, Indonesia, World Intellectual Property Organization (WIPO), Albania	Canada, United States of America, Austria, Australia, Germany, Denmark, Spain, Hong Kong, Japan, Korea, Republic of, New Zealand, Portugal, Singapore, Slovenia, Taiwan, Province of China, Belgium, Switzerland, Cyprus, Finland, France, United Kingdom, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, Netherlands, Sweden, World Intellectual Property Organization (WIPO), Lithuania, Latvia, Romania

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on tenofovir disoproxil fumarate (TDF)

https://medicinespatentpool.org/licence-post/tenofovir-disoproxil-fumarate-tdf/

MPP licence on paediatric formulations of dolutegravir (DTG)

https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/

Compulsory licence on dolutegravir in Colombia

https://www.statnews.com/wp-content/uploads/2024/04/NC_534_Licencia_obligatoria_aceptada.pdf

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Tenofovir disoproxil compounds Expiry date: 2017-07-25 The present invention relates to intermediates for phosphonomethoxy nucleotide analogs, in particular intermediates suitable for use in the efficient oral delivery of such analogs.	WO9804569	Compound	Gilead Sciences, Inc	Yes	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted		Luxembourg, United Kingdom
Filed		
Not in force	China, India, World Intellectual Property Organization (WIPO)	Canada, Austria, Australia, Germany, Denmark, Spain, Hong Kong, Japan, Korea, Republic of, Luxembourg, Netherlands, New Zealand, Portugal, Taiwan, Province of China, United States of America, Belgium, Switzerland, Finland, France, Greece, Ireland, Italy, Liechtenstein, Monaco, Sweden, Chile, World Intellectual Property Organization (WIPO), Singapore

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on tenofovir disoproxil fumarate (TDF)

https://medicinespatentpool.org/licence-post/tenofovir-disoproxil-fumarate-tdf/

MPP licence on paediatric formulations of dolutegravir (DTG)

https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/

Compulsory licence on dolutegravir in Colombia

https://www.statnews.com/wp-content/uploads/2024/04/NC_534_Licencia_obligatoria_aceptada.pdf

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Emtricitabine and lamivudine - process for preparing Expiry date: 2012-12-21 The present invention relates to processes for preparing substituted 1,3-oxathiolanes with antiviral activity and intermediates of use in their preparation.	WO9414802	Process	Biochem Pharma Inc	Yes	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted		
Filed		Denmark, Spain, Portugal
Not in force	World Intellectual Property Organization (WIPO)	Canada, Austria, World Intellectual Property Organization (WIPO), Australia, Germany, Denmark, Spain, Hungary, Japan, Portugal, Belgium, Switzerland, France, United Kingdom, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, Netherlands, Sweden

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on tenofovir disoproxil fumarate (TDF)

https://medicinespatentpool.org/licence-post/tenofovir-disoproxil-fumarate-tdf/

MPP licence on paediatric formulations of dolutegravir (DTG)

https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/

Compulsory licence on dolutegravir in Colombia

https://www.statnews.com/wp-content/uploads/2024/04/NC_534_Licencia_obligatoria_aceptada.pdf

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Lamivudine crystal forms Expiry date: 2012-06-02 (-)$i(cis)-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(IH)-pyrimidine-2-one in crystalline form, in particular as needle-shaped or bipyramidyl crystals, pharmaceutical formulations thereof, methods for their preparation and their use in medicine.	WO9221676	Polymorphs	Glaxo Group Limited	Yes	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted		United States of America
Filed		United Kingdom, Austria, Australia, Denmark, Ireland, Iceland, Portugal, Singapore
Not in force	Mexico, South Africa, Botswana, Ghana, Gambia (the), Kenya, Lesotho, Malawi, Sudan, Eswatini, Uganda, Zambia, Zimbabwe, Burkina Faso, Benin, Central African Republic, Congo, Côte d'Ivoire, Cameroon, Gabon, Guinea, Mali, Mauritania, Niger, Senegal, Chad, Togo, Philippines, Ukraine, Pakistan, Georgia, World Intellectual Property Organization (WIPO)	Canada, United Kingdom, Austria, Bulgaria, Germany, Denmark, Hong Kong, Ireland, Israel, Japan, Korea, Republic of, Norway, New Zealand, Portugal, Russian Federation, Slovakia, Taiwan, Province of China, Belgium, Switzerland, Spain, France, Greece, Italy, Liechtenstein, Luxembourg, Monaco, Netherlands, Sweden, World Intellectual Property Organization (WIPO)

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on tenofovir disoproxil fumarate (TDF)

https://medicinespatentpool.org/licence-post/tenofovir-disoproxil-fumarate-tdf/

MPP licence on paediatric formulations of dolutegravir (DTG)

https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/

Compulsory licence on dolutegravir in Colombia

https://www.statnews.com/wp-content/uploads/2024/04/NC_534_Licencia_obligatoria_aceptada.pdf

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Lamivudine compound Expiry date: 2011-05-02 (-)-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, its pharmaceutically acceptable derivatives, pharmaceutical formulations thereof, methods for its preparation and its use as an antiviral agent are described.	WO9117159	Compound	Iaf Biochem International Inc	Yes	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted		United States of America
Filed		United Kingdom, Australia, Finland, Hungary, Japan, Korea, Republic of, New Zealand, Poland, Singapore, Slovenia
Not in force	World Intellectual Property Organization (WIPO), Bosnia and Herzegovina, Yugoslavia/Serbia and Montenegro, China, Morocco, Moldova, Republic of, Tunisia, South Africa, Botswana, Ghana, Gambia (the), Kenya, Lesotho, Malawi, Sudan, Eswatini, Uganda, Zambia, Zimbabwe, Burkina Faso, Benin, Central African Republic, Congo, Côte d'Ivoire, Cameroon, Gabon, Guinea, Mali, Mauritania, Niger, Senegal, Chad, Togo, Egypt, Ukraine, Malaysia, Georgia	Canada, United Kingdom, World Intellectual Property Organization (WIPO), Bulgaria, Hong Kong, Croatia, Ireland, Israel, Japan, Korea, Republic of, Norway, Portugal, Romania, Slovakia, Taiwan, Province of China, United States of America, Austria, Belgium, Switzerland, Germany, Denmark, Spain, France, Greece, Italy, Liechtenstein, Luxembourg, Netherlands, Sweden

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on tenofovir disoproxil fumarate (TDF)

https://medicinespatentpool.org/licence-post/tenofovir-disoproxil-fumarate-tdf/

MPP licence on paediatric formulations of dolutegravir (DTG)

https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/

Compulsory licence on dolutegravir in Colombia

https://www.statnews.com/wp-content/uploads/2024/04/NC_534_Licencia_obligatoria_aceptada.pdf

Patent informations

Patent description	Representative patent	Categories	Patent holder	Licence with MPP	Patent source
Emtricitabine and lamivudine compounds Expiry date: 2010-02-08 Novel substituted 1,3-oxathiolane cyclic compounds having pharmacological activity, to processes for and intermediates of use in their preparation, to pharmaceutical compositions containing them, and to the use of these compounds in the antiviral treatment of mammals.	CA2009637	Compound	Biochem Pharma Inc, Iaf Biochem International, Inc	Yes	

Patent status

Patent status/countries	Low, Low- middle and upper-middle	High income
Granted		United States of America, Australia, Germany, Spain, Finland, Ireland, Portugal
Filed		United States of America, Australia, Cyprus, Germany, Denmark, Spain, Greece, Hungary, Ireland, Japan, Luxembourg, Latvia, Netherlands, New Zealand, Poland, Singapore, Slovenia, Slovakia

Patent status/countries	Low, Low- middle and upper-middle	High income
Not in force	Bosnia and Herzegovina, Yugoslavia/Serbia and Montenegro, China, Honduras, South Africa, Botswana, Ghana, Gambia (the), Kenya, Lesotho, Malawi, Sudan, Eswatini, Uganda, Zambia, Zimbabwe, Burkina Faso, Benin, Central African Republic, Congo, Côte d'Ivoire, Cameroon, Gabon, Guinea, Mali, Mauritania, Niger, Senegal, Chad, Togo, Malaysia, Philippines, Armenia, Kyrgyzstan, Tajikistan, Sri Lanka, Dominican Republic, Georgia, Uzbekistan, Mexico, Moldova, Republic of, Ukraine	Canada, United States of America, Austria, Germany, Denmark, Spain, Greece, Hong Kong, Croatia, Israel, Japan, Korea, Republic of, Luxembourg, Netherlands, Norway, Belgium, Switzerland, France, United Kingdom, Italy, Liechtenstein, Sweden, Uruguay, Saudi Arabia

MPP Licence(s)

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg/

MPP licence on tenofovir disoproxil fumarate (TDF)

https://medicinespatentpool.org/licence-post/tenofovir-disoproxil-fumarate-tdf/

MPP licence on paediatric formulations of dolutegravir (DTG)

https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg/

MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations in AZ, BY, KZ and MY

https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg-umics/

Compulsory licence on dolutegravir in Colombia

https://www.statnews.com/wp-content/uploads/2024/04/NC_534_Licencia_obligatoria_aceptada.pdf

Supporting material

Publications

Perazzolo S, Stephen ZR, Eguchi M, Xu X, Delle Fratte R, Collier AC, Melvin AJ, Ho RJY. A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable. AIDS. 2023 Nov 15;37(14):2131-2136. DOI: 10.1097/QAD.0000000000003706. Epub 2023 Aug 24. PMID: 37650755; PMCID: PMC10959254.

Objective: To develop an injectable dosage form of the daily oral HIV drugs, tenofovir (T), lamivudine (L), and dolutegravir (D), creating a single, complete, all-in-one TLD 3-drug-combination that demonstrates long-acting pharmacokinetics.

Design: Using drug-combination-nanoparticle (DcNP) technology to stabilize multiple HIV drugs, the 3-HIV drugs TLD, with disparate physical-chemical properties, are stabilized and assembled with lipid-excipients to form TLD-in-DcNP . TLD-in-DcNP is verified to be stable and suitable for subcutaneous administration. To characterize the plasma time-courses and PBMC concentrations for all 3 drugs, single subcutaneous injections of TLD-in-DcNP were given to nonhuman primates (NHP, M. nemestrina).

Results: Following single-dose TLD-in-DcNP , all drugs exhibited long-acting profiles in NHP plasma with levels that persisted for 4 weeks above predicted viral-effective concentrations for TLD in combination. Times-to-peak were within 24 hr in all NHP for all drugs. Compared to a free-soluble TLD, TLD-in-DcNP provided exposure enhancement and extended duration 7.0-, 2.1-, and 20-fold as AUC boost and 10-, 8.3-, and 5.9-fold as half-life extension. Additionally, DcNP may provide more drug exposure in cells than plasma with PBMC-to-plasma drug ratios exceeding one, suggesting cell-targeted drug-combination delivery.

Conclusions: This study confirms that TLD with disparate properties can be made stable by DcNP to enable TLD concentrations of 4 weeks in NHP. Study results highlighted the potential of TLD-in-DcNP as a convenient all-in-one, complete HIV long-acting product for clinical development.

Additional documents

- Transformation of 3 current short-acting HIV drugs, tenofovir, lamivudine and dolutegravir (TLD)

Useful links

- Targeted Long-Acting Combination Antiretroviral Therapy (TLC-ART) Program Updates Pipeline Report

Access principles

Collaborate for development

Consider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology

Not provided

Share technical information for match-making assessment

Provide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit

Not provided

Work with MPP to expand access in LMICs

In the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing

Not provided

Comment & Information

Not provided